All In Biotech

Drug Trial Radar · NCT03350386

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Drug-drug Interaction Study to Evaluate the Pharmacokinetics and Safety of FYU-981 and Oxaprozin in Healthy Male Adults Subjects

Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Nov 2, 2017

Primary completion

Dec 5, 2017

Study completion Dec 5, 2017

Sponsor

Sponsor type
Industry
Collaborators
Fuji Yakuhin Co., Ltd.
First posted
Nov 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 20 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

Conditions

  • Healthy

Interventions

  • FYU-981Drug

    Single administration

  • OxaprozinDrug

    Repeated administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (Cmax: Maximum plasma concentration)Time frame: 48 hours
  2. Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)Time frame: 48 hours
  3. Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)Time frame: 48 hours
  4. Pharmacokinetics (AUC: Area under the plasma concentration-time curve)Time frame: 48 hours
  5. Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)Time frame: 48 hours
  6. Pharmacokinetics (kel: Elimination rate constant)Time frame: 48 hours
  7. Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)Time frame: 48 hours
  8. Pharmacokinetics (MRT: Mean residence time)Time frame: 48 hours
  9. Safety (Incidence of treatment-emergent adverse event)Time frame: 20 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • P-One Clinic

    Hachiōji, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.